Abiopharma

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçets Disease Published in Rheumatology (Oxford)

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Edwards Lifesciences Corp - Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference